Malaysia MDA Announces Implementation of Hologram Security Labels for Registered Medical Devices

On August 5, 2026, Malaysia’s Medical Device Authority (MDA) announced the phased introduction of Hologram Security Labels for registered medical devices.

The initiative extends Malaysia’s use of physical product-authentication measures from pharmaceuticals to medical devices, adding a product-level control to the existing registration and post-market surveillance framework. The policy direction is clear, but the technical and implementation requirements have yet to be published. Further details are expected at the International Medical Device Exhibition and Conference (IMDEC) on August 26, 2026.

For medical device manufacturers, registration holders, Authorized Representatives (ARs), importers, and distributors, the practical question is how the new medical device labeling requirement will fit into existing manufacturing, packaging, import, registration, and distribution processes.

Extending the Pharmaceutical Security-Label Model to Medical Devices

Malaysia introduced the FarmaTag hologram label for pharmaceutical products in 2005 to help combat counterfeit medicines and authenticate products in the market.

Extending a similar model to medical devices gives the MDA an established framework for product-level verification and could strengthen post-market controls by making registered products physically identifiable within the supply chain.

Five Critical Questions Ahead of IMDEC

Industry eyes are on the upcoming IMDEC conference on August 26 for clarity on five major points:

• How will requirements be phased across medical device classifications and product categories?
• Do Hologram Security Labels have to be applied at overseas manufacturing sites, or can they be issued and applied in Malaysia?
• How will labels be associated with registered devices, batches, or other product records?
• How will existing inventory, products already manufactured, and shipments in transit be treated?
• Which parties will be responsible for obtaining, applying, controlling, documenting, and reconciling labels?

These decisions will directly affect packaging operations, import logistics, inventory management, and the division of responsibilities between foreign manufacturers and their Malaysian regulatory and commercial partners.

Impact on Malaysian Registration Holders, Authorized Representatives, and Distributors

The new requirement could make the allocation of regulatory and commercial responsibilities more consequential, particularly where registration and distribution are handled by different entities.

Distributor-Led Medical Device Registrations

Where a Malaysian distributor holds the device registration while the manufacturer controls production, the parties will need to establish clear responsibilities for Hologram Security Labels.

The issue becomes more complex when a manufacturer uses multiple distributors, as separate labeling processes could make it harder to maintain consistent controls across the Malaysian portfolio.

When an Independent Malaysian Authorized Representative May Matter

An independent AR can separate regulatory representation from individual distribution relationships. This may give the manufacturer a central point for coordinating registration-related requirements and communicating new labeling obligations across its distributor network. However, an AR does not remove the manufacturer’s need to maintain oversight.

Medical Device Supply Chain and Quality Implications

While manufacturers should wait for the specifications before changing packaging, they can begin assessing how different application models would affect operations.

Potential application points include:

• Overseas manufacturing sites: Labels could potentially be incorporated into existing packaging processes before products are exported to Malaysia. 
• In-country bonded warehouses: Labels could potentially be applied after importing but before products enter the domestic distribution network. 
• Malaysian distribution facilities: Labeling could be handled locally, but this would place additional operational and quality-control responsibilities on the distributor or other local partner. 

The final application model will have implications for packaging, product release, inventory control, logistics, and responsibility for label reconciliation.

If the MDA requires labels to be linked to specific registered products, batches, or other records, manufacturers will also need controls to document label issuance, application, and reconciliation.

Preparing for Malaysia’s Medical Device Hologram Label Requirement

Until the MDA publishes the detailed framework, manufacturers should focus on preparation rather than implementing changes based on assumptions.

Review Registration and Distribution Control

Determine where registration, inventory, importation, labeling, and distribution responsibilities sit for each product.

Where these functions are split among the manufacturer, AR, importer, and distributor, review contractual arrangements to ensure accountability is clearly established.

Model the Labeling and Inventory Impact

Assess how the requirement could work if labels are applied at the manufacturing site, in bonded storage, or at a Malaysian distribution facility. Compare the implications for packaging, product release, lead times, inventory controls, and label reconciliation.

At the same time, review Malaysian inventory to identify stock that could require additional handling or transition controls.

Integrate the Requirement into Existing Quality Controls

Assess how label issuance, application, reconciliation, and verification could fit within existing quality and traceability procedures. Where possible, manufacturers should extend established controls rather than create a separate compliance process for hologram management.

Final Thoughts

The key question is not what the final MDA requirements will be, but who will own the process and where it will sit within the supply chain. Manufacturers that clarify these responsibilities early will be better positioned to implement the new controls without adding unnecessary complexity or disrupting market operations.

With a local office in Malaysia, Cisema is positioned to help manufacturers work through that transition locally while connecting it to their wider Asia regulatory strategy. From local representation and market access to compliance and supply-chain coordination, our team helps turn regulatory requirements into workable operating models.

To assess how the new Hologram Security Label requirement may affect your Malaysian market-access strategy, contact Cisema today.

Further Information

Explore Cisema’s services for medical device registration in Malaysia

Our related article, Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices, examines another recent change to Malaysia’s medical device labeling requirements, providing additional context on the country’s evolving approach to medical device labeling.

‍

About the Author: Shouzheng Tan

Shouzheng Tan is Vice President of Southeast Asia at Cisema, based in Penang, Malaysia. He brings more than a decade of experience in the medical device industry, specializing in regulatory registration and market access across Southeast Asia. In his role, he works closely with overseas manufacturers to develop and implement effective regulatory strategies for medical devices throughout the region, including key markets such as Malaysia. His expertise is complemented by working knowledge of quality management systems, allowing him to support clients across both regulatory and compliance requirements.

References

Medical Device Authority (MDA), Press Release: Implementation of the Hologram Security Label for Medical Devices